Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors

Summary

This is a first-in-human, Phase 1, open label, multicenter, multiple dose, dose escalation and dose expansion study intended to evaluate the safety, pharmacokinetic, pharmacodynamic, and potential clinical benefit of PF-07209960, an anti-PD-1 targeting IL-15 fusion protein, in participants with selected locally advanced or metastatic solid tumors for whom no standard therapy is available, or would not be an appropriate option in the opinion of the participant and their treating physician, or participants who have refused standard therapy. The study contains 2 parts, single agent Dose Escalation (Part 1) to determine the recommended dose of PF-07209960, followed by Dose Expansion (Part 2) in selected tumor types at the recommended dose.

Timeline

Start

2020-12-16

Primary completion

2023-05-03

Completion

2023-05-26

Outcome

Outcome not reported

Stopped (Business): “Pfizer has made an internal business decision to not continue further development of PF-07209960. This decision was not based on safety or regulatory considerations”

Drugs

Indications